ArticleJournal of Alzheimer's disease reports
A 52-week, open-label, observational study evaluating tolerability, efficacy and physicians satisfaction of rivastigmine oral solution in Alzheimer's disease in Taiwan.
Chuo-Yu Lee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.